TY - JOUR
T1 - Low-dose aspirin in high-risk individuals with screen-detected subsolid lung nodules
T2 - A randomized phase II trial
AU - Bonanni, Bernardo
AU - Serrano, Davide
AU - Maisonneuve, Patrick
AU - Veronesi, Giulia
AU - Johansson, Harriet
AU - Aristarco, Valentina
AU - Varricchio, Clara
AU - Cazzaniga, Massimiliano
AU - Lazzeroni, Matteo
AU - Rampinelli, Cristiano
AU - Bellomi, Massimo
AU - Vecchi, Manuela
AU - Spaggiari, Lorenzo
AU - Vornik, Lana
AU - Brown, Powel H.
AU - Beavers, Therese
AU - Guerrieri-Gonzaga, Aliana
AU - Szabo, Eva
N1 - Publisher Copyright:
© The Author(s) 2020.
PY - 2021
Y1 - 2021
N2 - Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin's anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual lowdose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12months of treatment (-0.12mm[SD = 1.55 mm] and +0.30mm[SD= 2.54 mm], respectively; 2-sided P=.33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.
AB - Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin's anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual lowdose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12months of treatment (-0.12mm[SD = 1.55 mm] and +0.30mm[SD= 2.54 mm], respectively; 2-sided P=.33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.
UR - http://www.scopus.com/inward/record.url?scp=85100602817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100602817&partnerID=8YFLogxK
U2 - 10.1093/JNCICS/PKAA096
DO - 10.1093/JNCICS/PKAA096
M3 - Article
C2 - 33409459
AN - SCOPUS:85100602817
SN - 2515-5091
VL - 4
JO - JNCI Cancer Spectrum
JF - JNCI Cancer Spectrum
IS - 6
M1 - pkaa096
ER -